IL-RF-IDEAS
5.4.2022 21:16:05 CEST | Business Wire | Press release
rf IDEAS, a leading manufacturer of credential readers for authentication and logical access, is pleased to announce that select models of its WAVE ID® Plus, WAVE ID® Nano and WAVE ID® Nano OEM card reader families now support the FIDO2 NFC protocol. This technology brings seamless, passwordless authentication to security-critical enterprises in finance, healthcare, government, manufacturing, education and other markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220405006143/en/
FIDO2 frees enterprises from password management and risk
FIDO2 offers passwordless authentication without boundaries—across credential types, devices and platforms. This rapidly growing industry standard is supported by Microsoft, Google, Apple, and all leading web services and browsers.
FIDO2 supports login to devices, websites and applications using contactless credentials, biometrics, mobile devices and security keys. It eliminates the need for centrally stored passwords that can be hacked, as well as the risk of password theft, phishing and other user-directed attacks.
rf IDEAS enables FIDO2 on today’s security infrastructure
Through the rf IDEAS® Universal SDK, WAVE ID® readers work with nearly every proximity and contactless smart card in use worldwide. These readers also optionally support the card chip interface device protocol (CCID), providing plug-and-play functionality with most computing platforms and operating systems.
Any logical access application that supports WAVE ID readers can add the ability to use NFC FIDO2 security keys and cards with no disruption—while maintaining full backward-compatibility. Using FIDO2, enterprises can easily eliminate passwords to harden their single-factor security infrastructure. With multi-factor authentication becoming the new security standard, FIDO2 is ideal for supporting seamless access to all enterprise devices and data.
WAVE ID® readers with FIDO2: a more productive and secure future, today
“rf IDEAS has been a passwordless champion since its inception, providing convenient tap-and-go authentication without compromising security,” said Gourgen Oganessyan, Product Marketing Manager at rf IDEAS and the company’s representative at the FIDO Alliance. “With the addition of FIDO2 NFC functionality to our WAVE ID readers, users of rf IDEAS technology can benefit from the industry’s strongest, most secure passwordless authentication standard.”
To learn more about FIDO2 and WAVE ID readers, click here .
About rf IDEAS
rf IDEAS, Inc. is a leader in logical access solutions for healthcare, manufacturing, government, education and enterprise. The company’s WAVE ID readers (formerly pcProx® ) are trusted by users across the globe and backed by strong partnerships with leading identity access management providers. rf IDEAS readers enable innovative solutions for single sign-on, secure printing, attendance tracking and mobile authentication while supporting nearly all credentials worldwide. For more information, visit www.rfIDEAS.com .
rf IDEAS® and WAVE ID® are registered trademarks of rf IDEAS, Inc. All other trademarks, service marks and product or service names are property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405006143/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
